Skin Protein Deficiency Boosts Hypertension via Angiotensin

A groundbreaking study recently published in Nature Communications has unveiled a novel molecular mechanism by which hypertension, a critical global health issue, is exacerbated through skin-specific pathways. The remarkable discovery centers on the deficiency of the angiotensin II receptor-associated protein (ATRAP) specifically in keratinocytes—the predominant cell type in the outermost layer of the skin—which has been demonstrated to aggravate angiotensin II-dependent hypertension. This finding significantly shifts the traditional focus of hypertension research by implicating the skin’s local renin-angiotensin system (RAS) as a pivotal contributor to systemic blood pressure regulation.

For years, the renin-angiotensin system has been primarily studied within the contexts of renal and cardiovascular physiology, where its role in regulating blood pressure and fluid balance is well established. However, the skin has increasingly been recognized not merely as a passive barrier but as an active endocrine organ capable of synthesizing and responding to various bioactive molecules. The current study by Taguchi et al. pushes the boundaries of this understanding by showing that skin-specific molecular disturbances can profoundly influence systemic hypertensive processes, potentially unveiling new therapeutic avenues.

At the molecular core of this phenomenon is ATRAP, a known modulator of angiotensin II receptor type 1 (AT1R) signaling. The AT1R mediates many of the hypertensive and pathological effects of angiotensin II, a peptide hormone critical to cardiovascular regulation. ATRAP serves as a negative regulator, attenuating the receptor’s signaling activity, and thus its deficiency results in the heightened activation of angiotensin II pathways. In keratinocytes, the absence of ATRAP appeared to unleash unchecked AT1R signaling, exacerbating hypertension in response to angiotensin II.

.adsslot_lDfwP8ukm2{ width:728px !important; height:90px !important; }
@media (max-width:1199px) { .adsslot_lDfwP8ukm2{ width:468px !important; height:60px !important; } }
@media (max-width:767px) { .adsslot_lDfwP8ukm2{ width:320px !important; height:50px !important; } }

ADVERTISEMENT

Intricately, the investigators employed sophisticated genetic manipulation to create mouse models in which ATRAP was selectively knocked out in keratinocytes, leaving other tissues unaffected. This cell-specific targeting allowed for precise dissection of physiological consequences attributable solely to skin ATRAP deficiency. What emerged was a striking increase in systemic blood pressure when these mice were infused with angiotensin II, underscoring the pathological contribution of skin-derived RAS activation.

Digging deeper into the mechanistic pathways, the research revealed that keratinocyte ATRAP deficiency amplified not only local angiotensin II signaling but also the expression of renin and angiotensinogen—key components involved in the generation of angiotensin II—within the skin milieu. This suggests the existence of an autonomous or semi-autonomous skin RAS loop capable of exacerbating systemic hypertensive states when dysregulated.

The translational implications of this study are profound. Current anti-hypertensive therapies primarily target systemic RAS components such as angiotensin-converting enzyme inhibitors or AT1R blockers. However, these drugs might inadequately address local tissue-specific regulatory circuits like the one emerging from the skin. Conceivably, this discovery could pave the way for the development of novel topical or targeted interventions aimed at restoring ATRAP function or dampening skin RAS hyperactivity, thus complementing conventional systemic therapies.

Furthermore, the study challenges the long-held dogma that the skin’s involvement in systemic blood pressure is negligible. By revealing that keratinocytes can modulate cardiovascular function through molecular signaling networks, it expands the understanding of skin biology far beyond its classical roles in protection and thermoregulation. This underscores the skin’s complex endocrine and paracrine capacities and invites attention to other potentially unexplored pathways within this organ that may impact systemic health.

From a methodological standpoint, the investigators utilized state-of-the-art in vivo blood pressure monitoring, molecular biology assays, and histological examinations to characterize the hypertensive phenotype and molecular changes induced by keratinocyte ATRAP deletion. Their integrative approach allowed for both macroscopic physiological insights and detailed cellular mechanistic delineation, rendering the findings robust and highly convincing.

Moreover, the skin RAS activation was linked to increased oxidative stress and inflammatory signaling pathways, which are well-known contributors to vascular dysfunction and hypertension. The interplay between angiotensin II signaling, reactive oxygen species generation, and inflammatory cytokine production within keratinocytes likely forms a vicious cycle potentiating hypertensive pathology.

Intriguingly, this new evidence opens fresh questions about the role of environmental factors that affect the skin, such as ultraviolet radiation, allergens, or microbial imbalances, in modulating local RAS activity and subsequent systemic effects. Could chronic skin insults synergize with genetic factors like ATRAP deficiency to elevate hypertension risk? Further research will be essential to unravel these complex interactions.

Another noteworthy aspect is the potential clinical relevance of the skin RAS in human hypertensive patients. The study prompts a reevaluation of skin biopsies and biomarker profiling in hypertensive individuals, which might reveal hitherto unrecognized predictive or diagnostic indicators. Future clinical investigations could explore whether topical modulation of skin RAS has tangible benefits for blood pressure control in human populations.

Perhaps equally fascinating is the insight this research provides into the cross-talk between different organ systems. It reinforces the systemic integration of cardiovascular regulation, showing that components once thought peripheral can exert meaningful control over core physiological parameters. This knowledge could stimulate holistic therapeutic strategies aimed at multiple tissues rather than the isolated targeting of systemic blood pressure mechanisms.

In summary, this seminal work by Taguchi and colleagues illuminates a previously underappreciated axis in hypertension pathogenesis involving keratinocyte-specific ATRAP deficiency and resultant hyperactivation of the skin renin-angiotensin system. The conceptual leap from skin barrier function to a dynamic regulator of systemic vascular tone marks a turning point in cardiovascular and dermatological research alike, inviting new investigations and innovative treatment paradigms.

As hypertension continues to pose formidable challenges globally, insights such as these remind us that the answers may lie in unexpected places—even at the very surface of our bodies. Bridging dermatology and cardiovascular science could unlock novel strategies to combat one of the most pervasive health conditions worldwide, potentially transforming millions of lives through targeted, tissue-specific therapies.

Further studies expanding on this discovery will likely explore the molecular intricacies of ATRAP regulation, its interaction partners within keratinocytes, and the downstream effects on vascular smooth muscle and endothelial function. The elucidation of such pathways holds promise for new drug targets capable of fine-tuning hypertensive responses with greater precision and fewer side effects.

Ultimately, this research underscores the remarkable plasticity and complexity of physiological systems and highlights the skin’s emerging status as a crucial player in systemic homeostasis. It challenges researchers and clinicians alike to reconsider the traditional compartmentalization of organ systems and to embrace a more integrative approach to understanding and managing human disease.

Subject of Research: Keratinocyte-specific angiotensin II receptor-associated protein deficiency exacerbates angiotensin II-dependent hypertension via activation of the skin renin-angiotensin system.

Article Title: Keratinocyte-specific angiotensin II receptor-associated protein deficiency exacerbates angiotensin II-dependent hypertension via activation of the skin renin-angiotensin system.

Article References:
Taguchi, S., Azushima, K., Kitada, K. et al. Keratinocyte-specific angiotensin II receptor-associated protein deficiency exacerbates angiotensin II-dependent hypertension via activation of the skin renin-angiotensin system. Nat Commun 16, 4789 (2025). https://doi.org/10.1038/s41467-025-60041-8

Image Credits: AI Generated

Tags: angiotensin II receptor signalingATRAP and keratinocytesbioactive molecules in skinendocrine functions of skinhypertension and angiotensin IImolecular mechanisms of hypertensionnovel hypertension therapiesrenin-angiotensin system in skinskin protein deficiencyskin-specific pathways in healthskin’s role in blood pressure regulationsystemic blood pressure control